Peptide therapeutics: current status and future directions

被引：2593

作者：

Fosgerau, Keld ^{[1
]}

Hoffmann, Torsten ^{[1
]}

机构：

[1] Zealand Pharma AS, DK-2600 Copenhagen, Denmark

来源：

DRUG DISCOVERY TODAY | 2015年 / 20卷 / 01期

关键词：

DELIVERY; AGONIST; GLP-1;

D O I：

10.1016/j.drudis.2014.10.003

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.

引用

页码：122 / 128

页数：7

共 32 条

[1]

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat [J].

Bao, Weike ;

Holt, Lucy J. ;

Prince, Rob D. ;

Jones, Gavin X. ;

Aravindhan, Karpagam ;

Szapacs, Mathew ;

Barbour, April M. ;

Jolivette, Larry J. ;

Lepore, John J. ;

Willette, Robert N. ;

DeAngelis, Elena ;

Jucker, Beat M. .

CARDIOVASCULAR DIABETOLOGY, 2013, 12

[2]

Buchwald H., 2014, SURG OBES RELAT DIS

[3]

DELGADO C, 1992, CRIT REV THER DRUG, V9, P249

[4]

DiMarchi R.D, Patent No. [PCT/US2013/046229, 2013046229]

[5]

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans [J].

Finan, Brian ;

Ma, Tao ;

Ottaway, Nickki ;

Mueller, Timo D. ;

Habegger, Kirk M. ;

Heppner, Kristy M. ;

Kirchner, Henriette ;

Holland, Jenna ;

Hembree, Jazzminn ;

Raver, Christine ;

Lockie, Sarah H. ;

Smiley, David L. ;

Gelfanov, Vasily ;

Yang, Bin ;

Hofmann, Susanna ;

Bruemmer, Dennis ;

Drucker, Daniel J. ;

Pfluger, Paul T. ;

Perez-Tilve, Diego ;

Gidda, Jaswant ;

Vignati, Louis ;

Zhang, Lianshan ;

Hauptman, Jonathan B. ;

Lau, Michele ;

Brecheisen, Mathieu ;

Uhles, Sabine ;

Riboulet, William ;

Hainaut, Emmanuelle ;

Sebokova, Elena ;

Conde-Knape, Karin ;

Konkar, Anish ;

DiMarchi, Richard D. ;

Tschoep, Matthias H. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (209)

[6]

The novel GLP-1-gastrin dual agonist, ZP3022, increases ß-cell mass and prevents diabetes in db/db mice [J].

Fosgerau, K. ;

Jessen, L. ;

Tolborg, J. Lind ;

Osterlund, T. ;

Larsen, K. Schaeffer ;

Rolsted, K. ;

Brorson, M. ;

Jelsing, J. ;

Neerup, T. Skovlund Ryge .

DIABETES OBESITY & METABOLISM, 2013, 15 (01) :62-71

[7]

Fosgerau K, 2011, DIABETES, V60, pA418

[8]

A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1 and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice [J].

Gault, Victor A. ;

Bhat, Vikas K. ;

Irwin, Nigel ;

Flatt, Peter R. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (49) :35581-35591

[9]

Neuroactive peptides as putative mediators of antiepileptic ketogenic diets [J].

Giordano, Carmela ;

Marchio, Maddalena ;

Timofeeva, Elena ;

Biagini, Giuseppe .

FRONTIERS IN NEUROLOGY, 2014, 5

[10]

Peptide fibrillization [J].

Hamley, Ian W. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2007, 46 (43) :8128-8147

← 1 2 3 4 →